Targeting central pathway of Glucose‐Dependent Insulinotropic Polypeptide, Glucagon and Glucagon‐like Peptide‐1 for metabolic regulation in obesity and type 2 diabetes

Documenti analoghi

• Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity
  di: Jonathan Brix Winther, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide ‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis
  di: Muhammad Aaqib Shamim, et al.
  Pubblicazione: (2024)
• Glucagon‐like peptide‐1 receptor agonists and incidence of obesity‐related cancer in adults with diabetes: A target‐trial emulation study
  di: Lucas A. Mavromatis, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity
  di: Andy Bowe, et al.
  Pubblicazione: (2025)
• Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue
  di: Richard Sotorník, et al.
  Pubblicazione: (2025)